Shots:

• The approval is based on P-III TONES study assessing Sunosi (solriamfetol) vs PBO in 900 patients with excessive daytime sleepiness associated with narcolepsy or Obstructive Sleep Apnea (OSA)
• The P-III TONES study results: @12wks. improvement in PGIc scale (68-74% receiving 75mg & 78-90% receiving 150mg); improvement in wakefulness (assessed in the maintenance of wakefulness test)
• Sunosi (75mg & 150mg for narcolepsy) (37.5 mg- 75 mg &150 mg for OSA) is a NDRI inhibitor- developed and commercialized by Jazz (Ex. Asia) and has received FDA’s ODD for narcolepsy in the US

Click here to read full press release/ article | Ref: Jazz Pharmaceuticals  | Image:Cronin Movers Group